Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
amniOST: hAM for Stage II MRONJ
NCT05664815Phase 2Recruiting
- Sponsor
- CHU de Besançon
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of biological amniotic membrane in medication-related osteonecrosis of the jaw (MRONJ) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Number of patients with re-apparition of bone exposure. Started Sep 2023; status: recruiting.
02
Drugs
biological amniotic membrane
03
Conditions
medication-related osteonecrosis of the jaw (MRONJ)
Beyond the preview
Go deeper on NCT05664815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664815.